ArticleJournal of orthopaedic surgery and research2025
MiR-328-5p/BCL7A axis is involved in fracture healing by modulating osteoblast function.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelayed fracture healing severely impacts patients' quality of life and imposes economic burdens.
objectiveThis study aimed to investigate the role of miR-328-5p in fracture healing and its underlying molecular mechanisms, providing novel insights for the management of delayed fracture healing.
methodsSerum miR-328-5p levels were measured by RT-qPCR in 125 tibial fracture patients. The diagnostic potential of miR-328-5p for delayed healing was assessed through ROC curve analysis. Osteogenic differentiation of hFOB 1.19 cells was induced using osteogenic medium followed by evaluation of osteogenic markers and alkaline phosphatase (ALP) activity. Downstream targets of miR-328-5p were predicted via bioinformatics analysis and validated by dual-luciferase reporter experiments. Cell proliferation and apoptotic rates were determined using CCK-8 and flow cytometry, respectively.
resultsAmong the 125 patients, 56 presented with delayed fracture healing. Clinical data analysis disclosed a marked downregulation of miR-328-5p in the delayed healing group, demonstrating diagnostic value. During osteogenic differentiation of hFOB 1.19 cells, miR-328-5p expression increased progressively. Inhibition of miR-328-5p during differentiation markedly suppressed the expression of osteogenic markers (RUNX2, OCN, and OPN) and reduced ALP activity. Functional experiments demonstrated that miR-328-5p inhibition impaired osteoblast proliferation and promoted apoptosis. Mechanistic investigations identified BCL7A as a direct target mediating the regulatory effects of miR-328-5p on osteogenic differentiation.
conclusionsMiR-328-5p shows promise as a potential biomarker for delayed fracture healing. In vitro studies further revealed its regulatory role in osteoblast differentiation through BCL7A, potentially providing new directions for improving fracture healing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.